Feed PEN
PE

Penumbra

PEN · NYSE

$319.39 +0.19% (+$0.61)
1M -1.54%
Market Cap $12.6B
P/E Ratio 78.19x
Div. Yield -
ROE 11.09%

Bulios Fair Price

$182.13

43.0% downside

Current Price

$319.39

Undervalued Fair Value Overvalued

According to Bulios Fair Price, PEN is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
5/9
Valuation
10 /100
Expensive
P/E 78.19x
EV/EBITDA 56.52x
PEG 0.06x
Growth
98 /100
Growing
Rev. growth 18.33%
Book val. growth 12.64%
EPS growth N/A
Profitability
75 /100
Strong
Gross margin 67.84%
Net margin 10.67%
FCF margin 14.35%
Quality
54 /100
Average
ROIC 8.40%
ROE 11.09%
Asset turnover 0.76x
Debt
100 /100
Low
Debt/Equity 0.14x
Current ratio 5.75x
Net debt/EBITDA 0.03x
Stability
63 /100
Moderate
Beta 0.70x
Rev. volatility 6.10%
Profitable years 3

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about PEN
Online

About the company

Solventum Corporation is an American technology company that focuses on developing innovative solutions in the fields of chemistry and pharmaceuticals. It specializes in providing services related to research, development, and commercialization of chemical and pharmaceutical products. Solventum Corporation collaborates with pharmaceutical and biotechnology companies to optimize manufacturing processes and develop new active ingredients. The company's goal is to improve the efficiency and safety of chemical processes, with a focus on sustainability and technological innovations.

Sector

Healthcare

Industry

Medical - Devices

CEO

Adam Elsesser

Employees

4,700

Headquarters

Alameda

Upcoming events

04 NOV

Earnings

Upcoming earnings report

43d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.